Probiyotiklerin tümör baskılayıcı etkileri

KAHRAMAN, Münevver; KARAHAN, Aynur Gül

doi:10.5505/TurkHijyen.2018.15428

Probiyotiklerin tümör baskılayıcı etkileri

Münevver KAHRAMAN, (Akdeniz Üniversitesi, Tıp Fakültesi Hastanesi, Sağlık Bilimleri Araştırma ve Uygulama Merkezi, Antalya, Türkiye)

Aynur Gül KARAHAN (Süleyman Demirel Üniversitesi, Mühendislik Fakültesi Gıda Mühendisliği Bölümü, Isparta, Türkiye)

Türk Hijyen ve Deneysel Biyoloji Dergisi

5 1

Yıl: 2018 Cilt: 75 Sayı: 4 Sayfa Aralığı: 421 - 442 Metin Dili: Türkçe DOI: 10.5505/TurkHijyen.2018.15428 İndeks Tarihi: 22-07-2020

Probiyotiklerin tümör baskılayıcı etkileri

Öz:

Hipokrat’ın “Tüm hastalıklar bağırsakta başlar.”yaklaşımından sonra günümüzde de bağırsaklar“ikinci beyin” olarak adlandırılmakta ve bağırsaktakimikrobiyal denge-sağlık ilişkisi yoğun araştırmalarınkonusu olmaktadır. Bağırsaklarda çeşitli nedenlerlebozulan mikrobiyal dengenin yeniden oluşturulmasındaise probiyotiklerden yararlanılmaktadır. Özellikleson 20 yılda probiyotiklerin sağlık üzerine etkilerineyönelik pek çok bilimsel bulgu elde edilmiştir.Bunlar arasında modern çağın vebası olarak dakabul edilen kanser üzerine probiyotiklerin etkisiniincelemeye yönelik çalışmalar son derece ilginçtir vebu konu aydınlatılması gereken pek çok bilinmeyeniiçermektedir. Probiyotiklerin kanseri önleme ve tedavietmesinde çeşitli mekanizmalar geçerlidir. Örneğinkanser öncül maddelerini üreten patojenleri inhibeederek bağırsak mikroflorasının düzenlenmesindeve böylece bu zararlı bileşiklerin oluşumununönlenmesinde etkili olmaktadır. Probiyotiklerin,antimikrobiyal ürünlerin üretimi yoluyla patojenbakterileri engelleyici ve immunomodülatör hücreleriuyarıcı özellikleri gibi kanser oluşumunu önleyiciolumlu etkilerine ait de birçok bulgu elde edilmiştir.Kanseri tetikleyen etkenler oldukça karmaşık olmaklabirlikte, beslenme yoluyla alındığında probiyotiklerinmutasyona ve tümör oluşumuna yol açan bileşiklerinneden olduğu DNA hasarını önlediği gözlenmiştir. Ayrıcaprobiyotikler kısa zincirli yağ asitleri gibi kanserdenkorunmada yararlı olan metabolitleri üretmektedir.Probiyotiklerin kanseri önleyici etkilerini, tümöroluşumunu engelleme, tekrar etme olasılığını azaltmave oluşmuş kanser hücrelerini ve dokularını yıkımauğratma şeklinde gerçekleştirebildiklerini gösterençalışmalar bulunmaktadır. Probiyotiklerin yerleşim alanıolan kalın bağırsak dışında, mesane, meme ve karaciğergibi yerleşim alanı olmayan organ ve dokularda datümör oluşumu ve gelişimini engelleyici etkisi olduğugösterilmiştir. Probiyotiklerin sağlık üzerine etkilerinintoplum tarafından anlaşılması ticari preparatlarınkullanımını dünyada ve ülkemizde yaygınlaştırmıştır.Ancak probiyotiklerin kanserin önlenmesi ve tedavisindekullanılabilmesi için etki mekanizmalarını somut şekildeaçıklayan ve olumlu sonuçları klinik denemelerleispatlanmış birçok çalışmanın yapılması gerekmektedir.Bu derlemede, probiyotiklerin farklı kanser tiplerineetkilerini ispatlamak amacıyla in vitro ve in vivokoşullarda yapılmış öncü niteliğinde çeşitli çalışmalarbu alana ilgi duyan araştırıcılar için irdelenmiş vetartışılmıştır.

Anahtar Kelime:

Tumor suppressor effects of probiotics

Öz:

After the approach of Hippocrates, “All diseases start in the intestine”, now the intestines are called “second brain” and microbial balance-health relation intestines is the subject of intensive researches. Probiotics are used for the reconstitution of microbial balance which is destroyed by various reasons in the intestines. Especially in the last 20 years, many scientific findings have been obtained about the health effects of probiotics. It is interesting to study the effects of probiotics on cancer, which is also accepted as a modern age plague, and this subject contains many unknowns that need to be elucidated. There are various mechanisms in the effects of probiotics in cancer prevention and treatment. For example, they inhibit pathogens that produce cancer precursors, thereby regulating intestinal microflora and thus inhibiting the formation of these deleterious compounds. There are also many findings of the positive effects of inhibiting cancer formation, such as the ability of pathogens to inhibit pathogenic bacteria and stimulate immunomodulatory cells through the production of antimicrobial products. While the cancer-causing agents are quite complex, it has been observed that probiotics prevent DNA damage caused by compounds that reason mutation and tumor formation when intake via nutrition. In addition, probiotics produce metabolites, such as short-chain fatty acids, that are useful for cancer protection. There are studies showing that probiotics can inhibit cancer, effects by inhibiting tumor formation, reducing the chance of recurrence, and destroying cancer cells and tissues. It has been shown to inhibit tumor growth and development in organs and tissues other than the colon where the probiotics are located such as bladder, breast, and liver. The public understanding of the health effects of probiotics has made the use of commercial preparations widespread in the world and in our country. However, in order to use probiotics in prevention and treatment of cancer, clinical studies which will demonstrate the mechanisms of action probiotics, must be conducted. In this review, several pioneering studies on in vitro and in vivo to elucidate the effects of probiotics on different cancer types have been emphasized and discussed for researchers interested in this field.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Dünya Sağlık Örgütü (FAO/WHO), 2002; Working Group Report on Drafting Guidelines for the valuation of Probiotics in Food London, Ontario, Canada, April 30 and May 1.
2. Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for heath, J Appl Microbiol, 2006; 100(6):1171-85.
3. Yılmaz K, Altındiş M. Sindirim Sistemi Mikrobiyotası ve Fekal Transplantasyon, Nobel Med, 2017; 13(1): 9-15.
4. Lerner A, Neidhöfer S, Matthias T. The gut microbiome feelings of the brain: A perspective for non-microbiologists, microorganisms, 2017; 5, 66.
5. Avetisyan M, Schill EM, Heuckeroth RO. Building a second brain in the bowel, The Journal of Clinical Investigation, 2015; 125, 3.
6. Jayasinghe R. 2017; A look at the Second Brain: The Brain in the Gut, Researchgate, https:// www.researchgate.net/publication/315726781.
7. Fuller R. Probiotics in human medicine. Gut, 1991; 32, 439-42.
8. Tamime AY, Marshall VME. Microbiolgy and Biochemistry of Cheese and Fermented Milk, editör Law B.A. Microbiolgy and Technology of Fermented Milk, 2. Baskı, Blackie Academic & Proffesional Publ. London, 1997; 153-192.
9. Aragón F, Perdigón G, LeBlanc A.M. Modification in the diet can induce beneficial effects against breast cancer, World J Clin Oncol, 2014; 5(3): 455- 64.
10. Chong ESL. A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action, World J Microbiol Biotechnol, 2014; 30: 351–74.
11. Gao C, Ganesh B.P, Shi Z, Shah R.R, Fultz R, Major A, Venable S, Lugo M,et al. Gut microbee mediated suppression of inflammationassociated colon carcinogenesis by luminal histamine production. The American Journal of Pathology, 2017; Vol. 187, No. 10.
12. Ölgen S, Bıçak I, Nebioğlu D. Angiogenesis ve kanser tedavisinde yeni yaklaşımlar Ankara Ecz, Fak, Derg. 2002; 31 (3)193-214.
13. Dünya Sağlık Örgütü (WHO), 2016; Uluslararası Kanser Araştırma Bürosu, Kanser Raporu.
14. Türkiye İstatistik Kurumu, 2017; 2009-2016 Yılları Türkiye Kanser İnsidansı, www.tuik.gov. tr.
15. Dönmez M, Cankurtaran M, Diken F, Günendi P. Gıda beslenmesi ve kanser ilişkisi, Ulusal Meslek Yüksekokulları Öğrenci Sempozyumu (MYO-OS), 21-22 Ekim, Düzce. 2010.
16. Aliustaoğlu M, Temel kanser fizyopatolojisi, Klinik Gelişim, 2014; 46-495.
17. Bolognani F, Rumney CJ, Rowland IR. Influence of Carcinogen binding by lactic acid producing bacteria on tissue distribution and in vivo mutagenicity of dietary carcinogens, Food and Chem. Toxicol. 1997; 35: 535-45.
18. Barnum KJ, O’Connell MJ. Cell cycle regulation by checkpoints, Methods Mol Biol. 2014; 1170: 29–40.
19. Nezami H, Mykkanen H, Kankaanpaa P, Salminen S, Ahokas J. Ability of Lactobacillus and Propionibacterium strains to remove aflatoxin B, from the chicken duodenum. J Food Prot, 2000; 63: 549-52.
20. Kumar M, Verma V, Nagpal R, Kumar, A, Behare PV, Singh B, et al. Anticarcinogenic effect of probiotic fermented milk and chlorophyllin on aflatoxin-B1-induced liver carcinogenesis in rats, British Journal of Nutrition, 2012; 107, 1006–16.
21. Kıray E, Kariptaş E. Probiyotikler, prebiyotikler ve sinbiyotiklerin kolorektal kanser ilişkisi, Elektronik Mikrobiyoloji Dergisi TR, 2015; Cilt: 13(1): 28-46.
22. Alagözlü H. Karsinogeneziste diyet ve mikrobiyotanın yeri. 5. Ulusal Gastroenteroloji Cerrahi Kongresi. 1st Euroasian Gastroenterological Association Symposium. 5 – 8 Nisan, Antalya, 2017.
23. Perdigon G, Locascio M, Medici M, Pesce A, Holgado R, Oliver G. Interaction of bifidobacteria with the gut and their influence in the immune function BIOCELL, 2003; 27(1): 1-9 ISSN 0327 – 9545.
24. Coşkun T. Pro-, pre- ve sinbiyotikler, çocuk sağlığı ve hastalıkları Dergisi, 2006; 49: 128-148.
25. Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics, A Role in chemoprevention for colorectal cancer? Cancer Biology & Therapy, 2006; 5: 10, 1265-9.
26. Lidbeck A, Geltner U, Allingert K, Orrhage M, Ottovat L, Brismars B, et al. Impact of Lactobacillus acidophilus supplements on the faecal microflora and soluble faecal bile acids in colon cancer patients. Microbial Ecology in Health and Disease, 1991; 4: 81-8.
27. Schiffrin E, Rochat F, Link-Amster H, Aeschlimann J, Donnet-Hughes A. Immunomodulation of human blood cells following ingestion of lactic acid bacteria. J, Dairy Sci, 1996; 78, 491–7.
28. Marteau P, Minekus M, Havenaar R, Huis in’t Veld JH. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. J Dairy Sci. 1997; 80(6):1031-7.
29. Herich R, Levkut M. Lactic acid bacteria, probiotics and immune system, Vet, Med, Czech, 2002; 47 (6):169-80.
30. Bhakdi S, Jensen J,T. Alpha-Toxin of Staphylococcus aureus, Microbiological Reviews, 1991; 55 (4), 733-51.
31. Feyisetan O, Tracey C, Hellawell G.O. Probiotics, dendritic cells and bladder cancer, BJU International, 2011; 109: 1594 – 7.
32. Takeda K, Suzuki T, Shimada SI, Shida K, Nanno M, Okumura K. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota, Clinical and Experimental Immunology, 2006; 1365-2249.
33. Pertigon G, deMakfas ME, Alvarez S. Systemic Augmentation of the immun response in mice by feding fermented milks with Lactobacillus casei and Lactobacillus GG- derived enzymes. İmmunol. 1998; 63: 17-23.
34. Maroof H, Mohammad HZ, Mobarez AM, Mohamadabadi MA, Lactobacillus acidophilus Could Modulate the Immune Response Against Breast Cancer in Murine Model, Clin. Immunol. 2012; 32: 1353–59.
35. Lee A, Lee YJ, Yoo HJ, Kim M, Chang Y, Lee DS, Lee JH. Consumption of Dairy Yogurt Containing Lactobacillus paracasei ssp. paracasei, Bifidobacterium animalis ssp. lactis and HeatTreated Lactobacillus plantarum Improves Immune Function Including Natural Killer Cell Activity, nutrients, 2017; 9, 558.
36. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10. Science, 2000; 289, 1352-5.
37. Pool –Zobel BL, Neudecker C, Domizlaff I, Ji S, Schillinger U, Rumney C, et al. Lactobacillus and Bifidobacterium mediated antigenotoxicity in the colon of the rat, Nutriton and Cancer, 1996; 26, 365-80.
38. Zsivkovits M, Fekadu K, Sontag G, Nabinger U, Huber W.W, Kundi M, et al. Prevention of heterocyclic amine-induced DNA damage in colon and liver of rats by different lactobacillus strains, Carcinogenesis, 2003; 24 (12) :1913-8.
39. Koller VJ, Marian B, Stidl R, Nersesyan A, Winter H, Simic T, et al. Impact of lactic acid bacteria on oxidative DNA damage in human derived colon cells. Food and Chemical Toxicology, 2008; 46, 1221–9.
40. Göçer ÇEM, Ergin F, Küçükçetin A. Sindirim Sistemi Modellerinde Probiyotik Mikroorganizmaların Canlılığı, Akademik Gıda, 2016;14(2) 158-65.
41. Karahan A.G, Çakmakçı ML. Probiyotikler. Gıda, 1996; 21(4):297-302.
42. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007; 25(2): 177-84.
43. Saad N, Delattre C, Urdaci M, Schmitter JM, Bressollier, P. An overview of the last advances in probiotic and prebiotic field, Food Science and Technology 50, 2013; 1-16.
44. Sanders ME, Guarner F, Guerrant R, Holt P.R, Quigley E.M.M, Sartor R.B, et al. An update on the use and investigation of probiotics in health and disease. Gut, 2013; 62(5): 787–96.
45. Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol, 2010; 3:307–19.
46. Lauranne AAP, Levinus AD, Hoentjen F. Probiotics and prebiotics in ulcerative colitis. Best Practice & Research Clinical Gastroenterology, 2016; 30, 55e71.
47. Burns AJ, Rowland IR. Anti-Carcinogenicity of Probiotics and Prebiotics. Curr, Issues Intest, Microbiol, 2000; 1(1): 13-24.
48. AlFaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants, The Cochrane Library, 2011; 3: 1-46.
49. Sentongo T. A, Cohran V, Korff S, Sullivan C, Iyer K, Zheng X. Intestinal Permeability and Effects of Lactobacillus rhamnosus Therapy in Children With Short Bowel Syndrome. Journal of Pediatric Gastroenterology and Nutrition, 2008; 46: 41–7.
50. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blinded randomized control trial. J Pediatr, 2005; 147:197-201.
51. Goldin BR, Gorbach SL. Alterations in fecal microflora enzymes related to diet, age, lactobacillus supplements, and dimethylhydrazine. Cancer, 1977; 40(5 Suppl):2421-6.
52. Goldin BR, Gorbach SL. The Effect of Milk and Lactobacillus Feeding on Human İntestinal Bacterial Enzyme Activity. The American Journal of Clinical Nutrition,1984; 39: 756-61.
53. Türkiye Halk Sağlığı Kurumu, 2017; Kanser Daire Başkanlığı istatistik verileri.
54. Denariaz G, Dugas B, Kasper H, Schmucker D, Schrezenmeir J. Immunity And Probiotics, Nutrition and Health Collection, 1999; 7-49.
55. Coleman O.I, Nunes T. Role of the Microbiota in Colorectal Cancer: Updates on Microbial Associations and Therapeutic Implications. BioResearch, 2016; 5 (1).
56. Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol, 2015; 14; 21(6): 1691-702.
57. Yıldız E. Kanser ve Beslenme, Sağlık Bakanlığı, 2008; Yayın No: 728
58. Haenszel W, Berg J.W, Segi M, Kurihara M, Locke F.B. Large-bowel cancer in Hawaiian Japanese. J Natl Cancer Inst. 1973; 51(6):1765-79.
59. Femia AP, Luceri C. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis, 2002; 23 (11) : 1953-60
60. Gao C, Ganesh B.P, Shi Z, Shah R.R, Fultz R, Major A, et al. Gut MicrobeeMediated Suppression of Inflammation-Associated Colon Carcinogenesis by Luminal Histamine Production The American Journal of Pathology, 2017; 187 (10).
61. Hayatsu H, Hayatsu T. Suppressing effect of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human, Cancer Letters, 1993; 73:173-9
62. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double blind clinical trial. Eur, Urol, 1995; 27, 104–9
63. Dwivedi A, Nomikou N, Nigama PS, McHalea AP. The effects of microencapsulated Lactobacillus casei on tumour cell growth: In vitro and in vivo studies, International Journal of Medical Microbiology, 2012; 302: 293-9
64. Asano M, Karasawa E, Takayama T. Antitumor activity of Lactobacillus casei (LC 9018) against experimental mouse bladder tumor (MBT-2). J. Urol., 1986; 136, 719–21
65. Lim BK, Mahendran R, Lee YK, Bay BH, Chemopreventive Effect of Lactobacillus rhamnosus on Growth of a Subcutaneously Implanted Bladder Cancer Cell Line in the Mouse, Jpn. J. Cancer Res, 2002; 93, 36–41
66. Seow SW, Cai S, Rahmat JN, Bay BH, Lee YK, Chan YH, et al. Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors. Japanese Cancer Association, 2010; 101 (3): 751–8
67. Reddy BS, Rivenson A. Inhibitory Effect of Bifidobacterium longum on Colon, Mammary, and Liver Carcinogenesis Induced by 2-Amino-3- methylimidazo [4,5] quinoline, a Food Mutagen, Cancer Res. 1993; 53: 3914-18
68. Li J, Sung CYJ, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, El-Nezami H. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. E1306–E1315/ Proceedings National Academy of Sciences, 2016; 16, 1306–15
69. Cargill M. Probiotics Are Here to Stay. Holistic Medicine for People and Pets, 2009; (617) 247- 1446
70. Karahan N, İşler M, Koyu A, Karahan AG, Kılıç GB, Çiriş İM, Set al. Effects of probiotics on methionine choline deficient diet-induced steatohepatitis in rats, Turk J Gastroenterol, 2012; 23 (2): 110-21
71. Chang W.H, Liu J.J, Chen C.H, Huang T.S, Lu F.J. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by fermented soy milk. Nutr. Cancer, 2002; 43, 214–226
72. Lee JH, Nam SH, Seo VT, Yun HD, Hong SY, et al. The production of surfactin during the fermentation of cheonggukjang by potential probiotic Bacillus subtilis CSY191 and the resultant growth suppression of MCF-7 human breast cancer cells, Food Chemistry, 2012; 131, 1347–54
73. Toi M, Hirota S, Tomotaki A, Sato N, Nozumi Y, Anan K, Nagashima T,Tokuda Y, Masuda N, Ohsumi N. Probiotic beverage with soy isoflavone consumption for breast cancer prevention: A case-control study. Curr. Nutr. Food Sci. 2013; 9, 194–200
74. Mego M, Holec V, Drgona L, Hainova K, Ciernikova S, Zajac V. Probiotic bacteria in cancer patientsundergoing chemotherapy and radiationtherapy, Complementary Therapies in Medicine, 2013; 21, 712—723
75. Marschalek J, Farr A, Marschalek ML, Domig KJ, Kneifel W, Singer CF, Kiss et al. Influence of Orally Administered Probiotic Lactobacillus Strains on Vaginal Microbiota in Women with Breast Cancer during Chemotherapy: A Randomized Placebo-Controlled Double-Blinded Pilot Study. Breast Care, 2017;12:335-9
76. Golkhalkhali B, Paliany AS, Chin KF, Rajandram R. The Roles of Adjuvant Supplements in Colorectal Cancer Patients on Chemotherapy – Reaping Benefits from Metabolic Crosstalk. Nutrition and Cancer. 2018; 70 (2): 1–8
77. Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J, Jet al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery - a double-blind study, Aliment Pharmacol Ther, 2011; 33(1):50-63

APA	KAHRAMAN M, KARAHAN A (2018). Probiyotiklerin tümör baskılayıcı etkileri. , 421 - 442. 10.5505/TurkHijyen.2018.15428
Chicago	KAHRAMAN Münevver,KARAHAN Aynur Gül Probiyotiklerin tümör baskılayıcı etkileri. (2018): 421 - 442. 10.5505/TurkHijyen.2018.15428
MLA	KAHRAMAN Münevver,KARAHAN Aynur Gül Probiyotiklerin tümör baskılayıcı etkileri. , 2018, ss.421 - 442. 10.5505/TurkHijyen.2018.15428
AMA	KAHRAMAN M,KARAHAN A Probiyotiklerin tümör baskılayıcı etkileri. . 2018; 421 - 442. 10.5505/TurkHijyen.2018.15428
Vancouver	KAHRAMAN M,KARAHAN A Probiyotiklerin tümör baskılayıcı etkileri. . 2018; 421 - 442. 10.5505/TurkHijyen.2018.15428
IEEE	KAHRAMAN M,KARAHAN A "Probiyotiklerin tümör baskılayıcı etkileri." , ss.421 - 442, 2018. 10.5505/TurkHijyen.2018.15428
ISNAD	KAHRAMAN, Münevver - KARAHAN, Aynur Gül. "Probiyotiklerin tümör baskılayıcı etkileri". (2018), 421-442. https://doi.org/10.5505/TurkHijyen.2018.15428

APA	KAHRAMAN M, KARAHAN A (2018). Probiyotiklerin tümör baskılayıcı etkileri. Türk Hijyen ve Deneysel Biyoloji Dergisi, 75(4), 421 - 442. 10.5505/TurkHijyen.2018.15428
Chicago	KAHRAMAN Münevver,KARAHAN Aynur Gül Probiyotiklerin tümör baskılayıcı etkileri. Türk Hijyen ve Deneysel Biyoloji Dergisi 75, no.4 (2018): 421 - 442. 10.5505/TurkHijyen.2018.15428
MLA	KAHRAMAN Münevver,KARAHAN Aynur Gül Probiyotiklerin tümör baskılayıcı etkileri. Türk Hijyen ve Deneysel Biyoloji Dergisi, vol.75, no.4, 2018, ss.421 - 442. 10.5505/TurkHijyen.2018.15428
AMA	KAHRAMAN M,KARAHAN A Probiyotiklerin tümör baskılayıcı etkileri. Türk Hijyen ve Deneysel Biyoloji Dergisi. 2018; 75(4): 421 - 442. 10.5505/TurkHijyen.2018.15428
Vancouver	KAHRAMAN M,KARAHAN A Probiyotiklerin tümör baskılayıcı etkileri. Türk Hijyen ve Deneysel Biyoloji Dergisi. 2018; 75(4): 421 - 442. 10.5505/TurkHijyen.2018.15428
IEEE	KAHRAMAN M,KARAHAN A "Probiyotiklerin tümör baskılayıcı etkileri." Türk Hijyen ve Deneysel Biyoloji Dergisi, 75, ss.421 - 442, 2018. 10.5505/TurkHijyen.2018.15428
ISNAD	KAHRAMAN, Münevver - KARAHAN, Aynur Gül. "Probiyotiklerin tümör baskılayıcı etkileri". Türk Hijyen ve Deneysel Biyoloji Dergisi 75/4 (2018), 421-442. https://doi.org/10.5505/TurkHijyen.2018.15428